Table I.
Baseline characteristics of the women with polycystic ovary syndrome enrolled in the clinical studies.
| Subject | Age (years) |
BMI (kg/m2) |
Months since last menses |
LH (IU/L) | FSH (IU/L) | Estradiol (pmol/L) |
Testosterone (nmol/L) |
FAI | Inhibin B (pg/mL) |
PCOS phenotype |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 32 | 22 | 7 | 10.3 | 4.1 | 139 | 2.5 | 3.0 | 135.3 | A |
| 2 | 24 | 22 | 6 | 9.3 | 4.8 | 140 | 1.5 | 3.2 | 89.4 | D |
| 3 | 32 | 31 | 13 | 2.2 | 3.6 | 84 | 0.6 | 2.7 | 90.7 | D |
| 4 | 34 | 25 | 18 | 17.1 | 3.3 | 161 | 3.2 | 4.8 | 137 | A |
| 5 | 30 | 29 | 12 | 6.5 | 4.7 | 94 | 0.7 | 1.2 | 80.7 | D |
| 6 | 28 | 33 | 5 | 8.5 | 3.9 | 93 | 1.8 | 4.5 | 75.4 | D |
| 7 | 23 | 25 | 3 | 13.8 | 4.0 | 138 | 1.2 | 1.4 | 62.5 | D |
| 8 | 29 | 33 | 3 | 9.5 | 3.6 | 53 | 1.1 | 5.0 | 30.6 | D |
| 9 | 32 | 26 | 24 | 4.3 | 3.3 | 91 | 0.6 | 0.8 | 77.5 | D |
| 10 | 25 | 17 | 24 | 11.5 | 4.6 | 130 | 2.5 | 3.0 | 127.6 | A |
| 11 | 25 | 22 | 6 | 12.4 | 3.6 | 121 | 1.9 | 3.2 | 111.8 | A |
| 12 | 34 | 25 | 22 | 23.5 | 3.9 | 276 | 3.2 | 4.8 | 140.3 | A |
| Mean ± SEM | 29 ± 1.2 | 26 ± 1.7 | 12 ± 2.6 | 10.7 ± 1.6 | 3.7 ± 0.1 | 124.0 ± 16.2 | 1.7 ± 0.3 | 3.1 ± 0.4 | 88.0 ± 15.3 |
All women had polycystic ovaries at ultrasound. Polycystic ovary syndrome (PCOS) phenotype A = oligo/amenorrhea, clinical or biochemical hyperandrogenism and polycystic ovaries; phenotype D = oligo/amenorrhea and polycystic ovaries. Reference range for testosterone, 0.3–1.9 nmol/l, and for FAI (Free Androgen Index), <5.2.